Narrow Results Clear All
Search results for "Press Release/Announcement"
- Press Release/Announcement
- Near Miss
FDA Drug Safety Communication: FDA warns about prescribing and dispensing errors resulting from brand name confusion with antidepressant Brintellix (vortioxetine) and antiplatelet Brilinta (ticagrelor).
MedWatch Safety Alert. Silver Spring, MD: US Food and Drug Administration; July 30, 2015.
Look-alike and sound-alike drug names can contribute to confusion and result in medication errors. To raise awareness of potential wrong-patient errors due to similarity between two proprietary names, this announcement describes near misses with the drugs at the prescribing and dispensing stage and suggests clinicians use the generic names for the medications to reduce risk of patient harm.
Rapid Response Report 2. London, UK: National Patient Safety Agency; September 3, 2007.
This announcement details the potential for errors and near misses associated with an injectable medication that is available in several formulations.